Table 1.
Patient characteristics of the entire cohort (N = 1135)
| Country | |
| Canada | 276 (24%) |
| Spain | 260 (23%) |
| UK | 152 (13%) |
| Switzerland | 96 (8%) |
| Italy | 77 (7%) |
| Germany | 74 (7%) |
| Russia | 69 (6%) |
| Australia | 53 (5%) |
| Portugal | 49 (4%) |
| France | 29 (3%) |
| Age at diagnosis | |
| Median (range) | 31.1 (10.5‐74.0) |
| Primary site | |
| Testis | 1 046 (92%) |
| Retroperitoneal | 19 (2%) |
| Mediastinal | 33 (3%) |
| Other | 36 (3%) |
| Unknown | 1 (<1%) |
| Histology | |
| Seminoma | 308 (27%) |
| Non‐seminoma/Mixed | 821 (72%) |
| Unknown | 6 (1%) |
| AJCC stage (at time of chemotherapy) | |
| 1S | 61 (5%) |
| 2a | 7 (1%) |
| 2A | 194 (17%) |
| 2B | 162 (14%) |
| 2C | 111 (10%) |
| 3 | 578 (51%) |
| Unknown | 22 (2%) |
| IGCCCG risk classification | |
| Good | 727 (64%) |
| Intermediate | 224 (20%) |
| Poor | 182 (16%) |
| Unknown | 2 (<1%) |
| Chemotherapy regimenb | |
| BEP | 931 (82%) |
| EP | 88 (8%) |
| VIP | 26 (2%) |
| TIP | 3 (<1%) |
| Other | 86 (8%) |
| Body surface areac | |
| Median | 1.97 |
| BSA >2 | 461 (44%) |
| Body mass indexc | |
| Median | 25.2 |
| BMI >35 | 37 (4%) |
| Khorana score | |
| 1 | 714 (63%) |
| 2 | 230 (20%) |
| 3 | 71 (6%) |
| 4 | 9 (1%) |
| Unknown | 111 (10%) |
| Smoking status | |
| Nonsmoker | 538 (47%) |
| Current‐smoker | 324 (29%) |
| Ex‐smoker | 111 (10%) |
| Unknown | 162 (14%) |
| Vascular access device inserted | |
| Yes | 218 (19%) |
| No | 640 (56%) |
| Unknown | 277 (24%) |
| Renal function during chemotherapyd | |
| Median GFR (range) | 120 mL/min (9‐309) |
| GFR <75 mL/min | 64 (8%) |
| Hospitalizations | |
| Yes | 491 (43%) |
| No | 367 (32%) |
| Unknown | 277 (25%) |
| Coagulopathy or known past history VTE | |
| Coagulopathy/VTE | 14 (1%) |
| LDH | |
| <1.5× ULN | 735 (65%) |
| 1.5‐5× ULN | 270 (24%) |
| 5‐10× ULN | 58 (5%) |
| >10× ULN | 40 (4%) |
| Unknown | 32 (2%) |
| Retroperitoneal lymph node size | |
| Median sizee | 3.0 cm |
| RPLN >5 cm | 288 (25%) |
| RPLN ≤5 cm | 846 (74%) |
| Unknown | 1 (1%) |
| RPLN >3.5 cm | 431 (38%) |
| RPLN ≤3.5 cm | 580 (52%) |
| Unknown | 124 (10%) |
| Prolonged prophylactic anticoagulation >7 days | |
| Yes | 81 (7%) |
| No | 1 035 (91%) |
| Unknown | 19 (2%) |
| Venous thromboembolism (VTE) | |
| Occurrence of VTE | 150 (10%) |
a
Identified as stage 2 but further sub‐classification unavailable.
b
BEP = Bleomycin, Etoposide, Cisplatin; BSA = Body Surface Area; EP = Etoposide, Cisplatin; VIP = Etoposide, Ifosfamide, Cisplatin; TIP = Paclitaxel, Ifosfamide, Cisplatin.
c
Available for 1051 (93%) of patients.
d
Available for 764 (70%) of patients.
e
Based upon for 1011 (89%) of patients with actual measurement recorded.